## **CHAPTER 13**

## Hemorrhoids

James E. Everhart, M.D., M.P.H.

Hemorrhoids are classified as diseases of the circulatory system by ICD-9 and ICD-10 (Appendix 1), but are much more often diagnosed and treated by digestive disease specialists than by those with a primary interest in the circulatory system. Therefore, burden data for hemorrhoids are presented in this report. Hemorrhoids are subclassified by anatomical location (internal or external) and whether they are complicated with bleeding, prolapse, strangulation, or ulceration. Hemorrhoids are common, and their treatment is primarily in the ambulatory care setting. In 2004, there were an estimated 2 million ambulatory care visits with hemorrhoids as first-listed diagnosis and 3.2 million visits at which hemorrhoids were an all-listed diagnoses (Table 1), which made hemorrhoids the fourth or fifth leading outpatient digestive system diagnosis (after GERD, abdominal wall hernia, and functional disorders, and essentially tied with diverticular disease). Visit rates were highest among persons age 65 years and older and among whites. Age-adjusted rates were similar for males and for females. Most hospitalizations for hemorrhoids are for surgery, which is performed most often as same-day surgery; thus, the number of hospitalizations for hemorrhoids was small relative to the number of ambulatory care visits (Table 1). As opposed to rates of ambulatory care visits, age-adjusted hospitalization rates were higher for blacks than whites. Hemorrhoids were most often listed as a secondary diagnosis (87 percent).

Age-adjusted ambulatory care visits for hemorrhoids declined slightly between the periods of 1992–1993 and 2003–2005 (Figure 1). The rate of visits in this latter period was about 20 percent lower than in the early 1980s, continuing a trend in declining outpatient visits that began in the 1960s.¹ Overnight hospitalizations with hemorrhoids listed as a diagnosis declined by about 60 percent from 1981 to 1994, and were relatively stable for the following 10 years. As a first-listed hospital diagnosis, hemorrhoids declined much more: from about 70 per 100,000 in 1979 to 13 per 100,000 in 2004.²

Death from hemorrhoids has always been exceedingly rare (Table 2 and Figure 2). There was a substantial decline from 1980 through 2004 in hemorrhoids noted as a diagnosis on death certificates.

Nearly 2 million prescriptions for hemorrhoids were filled at retail pharmacies in 2004, according to Verispan (Appendix 2), with topical medications such as pramoxine (pramocaine) and hydrocortisone and stool softeners such as psyllium most often prescribed (Table 3). Most persons with hemorrhoids do not seek medical care and are self-treated using nonprescription medications similar to those listed in Table 3; thus the totals in this table were a small portion of the number and cost of medications used to treat hemorrhoids.<sup>3</sup>

<sup>1</sup> Johanson JF. Hemorrhoids. In: Everhart JE, editor. Digestive diseases in the United States: epidemiology and impact. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office, 1994; NIH Publication No. 94-1447 pp. 271–298.

<sup>2</sup> Ibid.


<sup>3</sup> Ibid.

**Table 1.** Hemorrhoids: Number and Age-Adjusted Rates of Ambulatory Care Visits and Hospital Discharges With First-Listed and All-Listed Diagnoses by Age, Race, and Sex in the United States, 2004

		AM	MBULATORY CARE VISITS			HOSPITAL DISCHARGES			
DEMOGRAPHIC CHARACTERISTICS		First-Listed Diagnosis		All-Listed Diagnoses		First-Listed Diagnosis		All-Listed Diagnoses	
		Number in Thousands	Rate per 100,000	Number in Thousands	Rate per 100,000	Number in Thousands	Rate per 100,000	Number in Thousands	Rate per 100,000
AGE (Years)	Under 15	_	_	_	_	_	_	1	1
	15-44	716	569	1,131	899	8	7	57	46
	45-64	915	1,294	1,331	1,883	13	19	96	136
	65+	387	1,065	790	2,174	16	45	152	418
RACE	White	1,819	724	2,915	1,161	29	11	245	96
	Black	145	421	234	656	6	19	45	150
SEX	Female	944	621	1,745	1,132	19	12	179	110
	Male	1,092	751	1,531	1,061	19	14	127	95
TOTAL		2,036	693	3,275	1,115	38	13	306	104

SOURCE: National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS) (3-year average, 2003–2005), and Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP NIS)

**Figure 1.** Hemorrhoids: Age-Adjusted Rates of Ambulatory Care Visits and Hospital Discharges With All-Listed Diagnoses in the United States, 1979–2004




SOURCE: National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS) (averages 1992–1993, 1994–1996, 1997–1999, 2000–2002, 2003–2005), and National Hospital Discharge Survey (NHDS)

**Table 2.** Hemorrhoids: Number and Age-Adjusted Rates of Deaths and Years of Potential Life Lost (to Age 75) by Age, Race, and Sex in the United States, 2004

DEMOGRAPHIC CHARACTERISTICS		UNDE	RLYING CAUSE	UNDERLYING OR OTHER CAUSE		
		Number of Deaths	Rate per 100,000	Years of Potential Life Lost in Thousands	Number of Deaths	Rate per 100,000
AGE (Years)	Under 15	_	_	_	_	_
	15-44	2	0.0	0.1	5	0.0
	45-64	8	0.0	0.2	22	0.0
	65+	4	0.0	0.0	30	0.1
RACE	White	9	0.0	0.1	42	0.0
	Black	2	0.0	0.0	9	0.0
SEX	Female	3	0.0	0.0	21	0.0
	Male	11	0.0	0.2	36	0.0
TOTAL		14	0.0	0.2	57	0.0

SOURCE: Vital Statistics of the United States

Figure 2. Hemorrhoids: Age-Adjusted Rates of Death in the United States, 1979–2004



SOURCE: Vital Statistics of the United States

 Table 3. Hemorrhoids: Costliest Prescriptions

DRUG	Prescription (#)	Prescription	Retail Cost	Cost
Pramoxine/Hydrocortisone	336,508	16.9%	\$19,424,146	45.1%
Hydrocortisone	989,521	49.8	14,852,947	34.5
Hydrocortisone/Lidocaine	98,928	5.0	6,288,920	14.6
Docusate®	511,791	25.7	1,672,743	3.9
Hydrocodone/Acetaminophen	15,223	0.8	437,436	1.0
Oxycodone/Acetaminophen	2,550	0.1	116,818	0.3
Psyllium	7,715	0.4	80,312	0.2
Polycarbophil	14,496	0.7	43,635	0.1
Bismuth subgallate/Zinc oxide/Balsam	4,099	0.2	42,819	0.1
lbuprofen/Hydrocodone	858	0.0	25,637	0.1
Other	4,296	0.2	39,848	0.0
TOTAL	1,985,985	100.0%	\$43,025,261	100.0%

SOURCE: Verispan